Peptide detail

GLP-1

GLP-1 (Glucagon-Like Peptide-1) is an endogenous incretin hormone produced in the intestines after food consumption. Synthetic GLP-1 receptor agonists like semaglutide, liraglutide, and tirzepatide mimic this hormone's effects but with extended half-lives. These medications bind to GLP-1 receptors throughout the body, particularly in the pancreas and brain, producing multiple metabolic effects. They stimulate insulin release from pancreatic beta cells in a glucose-dependent manner, improving blood sugar control without causing hypoglycemia. In the brain, they activate satiety centers and slow gastric emptying, reducing hunger and food intake. GLP-1 agonists also protect pancreatic beta cells, potentially preserving insulin production capacity. Originally developed for type 2 diabetes treatment, these medications have shown remarkable effectiveness for weight management, with newer agents like semaglutide and tirzepatide producing average weight losses of 15-20% in clinical trials. Recent research suggests potential benefits for cardiovascular health, fatty liver disease, and possibly neurodegenerative disorders like Alzheimer's and Parkinson's disease.